We hope there will be a transfer of technology so PT Kalbe Farma can produce it (the vaccine) in the house.
Jakarta – The Drug and Food Control Company (BPOM) has stated it supports the domestic advancement of coronavirus drugs and vaccines, including the COVID-19 GX-19 N vaccine developed by Indonesia’s PT Kalbe Farma and South Korea’s Genexine.
” We hope there will be a transfer of innovation so PT Kalbe Farma can produce it (the vaccine) at home,” BPOM chief Penny Lukito said at an online interview here on Friday.
The development of the vaccine has reached the preparation phase for the 2nd and third phases of scientific tests in Indonesia, she informed
The medical tests in Indonesia are an excellent opportunity since the nation has a big population, she observed.
The medical tests should fulfill clinical aspects and uphold research study ethics, in accordance with the assistance on good practice of scientific testing, she said.
The Phase 2b/3 medical tests for the vaccine started at the end of June, 2021 and an interim analysis is anticipated to be performed for checking its security and effectiveness at the end of this year, she added.
Related news: Eager to see Indonesia produce indigenous COVID-19 vaccines: Thohir
PT Kalbe Farma chief commissioner Irawati Setiady has declared Stage 2b. B of the clinical test has actually achieved success and emergency-use authorization for the vaccine has been protected from BPOM. The GX-19 N vaccine can match the existing vaccines, she stated.
” To that end, Genexine is committed to supplying 10 million doses of the vaccine and later transferring technology for the production of the vaccine to Indonesia,” she notified.
Kalbe Farma director Sie Djohan revealed the hope the Indonesian individuals would receive the vaccine at the end of this year.
He said he might not offer details on the price of the vaccine given that it is under development.
” We have agreed that the job is non-profit. We desire the vaccine to be useful for the neighborhood,” he mentioned.
Associated news: Red-and-White vaccine to target any age groups: Brodjonegoro
